EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Rise of Enabling Technologies in Pharmaceutical Formulation Development and Manufacturing
Director, Formulation Development, Exelixis, Inc
Kasturi Pawar is a leading pharmaceutical scientist with a PhD in pharmaceutical sciences She has significantly contributed to the field of pharmaceutics Her research and experience have been focused on formulation development drug delivery and clinical supply chain Currently working as a Director in Formulation Development at Exelixis Inc she holds several publications and patents on drug deliver...
Articles
The Transformative Impact of AI on Regulatory Affairs
Regulatory affairs in the pharmaceutical industry encompass a broad and complex field that is essential for the development approval and postmarketing surveillance of pharmaceutical products This domain acts as the critical nexus between pharmaceutical companies
Research Insights
Spatial Structure Facilitates Evolutionary Rescue by Drug Resistance
Bacterial populations often have complex spatial structures which can impact their evolution Here we study how spatial structure affects the evolution of antibiotic resistance in a bacterial population
Case Studies
Case Study: A Simple And Sensitive Method To Analyze Genotoxic Impurityhydrazine In Pharmaceutical Materials
Abstract Hydrazine NH is a known genotoxic impurity that typically needs to be controlled down to low ppm level in pharmaceutical development Hydrazine however is a challenging molecule to analyze using conventional analytical techniques due to its physical and chemical properties eg lack of chromophore absence of any carbon atom low molecular weigh
Techno Trends
Polpharma Biologics Discovered First-of-its-Kind Natalizumab Biosimilar
Natalizumab the biosimilar aims to replicate the characteristics of the reference medication including its dosage form route of administration dosing regimen and presentation
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Nanoemulsion - A Promising Nanocarrier for Dermal Drug Delivery in Psoriasis
Sindhoor S M is currently working as an Assistant Professor in the Department of Pharmaceutics at Sri Adichunchanagiri College of Pharmacy, Mandya, Karnataka. His areas of specialisation include nanotechnology-based drug delivery system, lipid-based formulations, Topical delivery and gastroretentive in situ gel systems. He has published eight papers based on nanotechnology and lipid-based drug delivery system in peer reviewed indexed journals. Presently he is involved in the development of lipid-based delivery systems.
Marina Koland, is Professor and Head of the Department of Pharmaceutics at the NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangalore. Her area of specialisation in research is mucoadhesive and nanoparticulate drug delivery. She has published 50 research papers in peer reviewed journals, presented papers at 10 National and 3 International Conferences and worked on several Nitte University funded projects. She is currently working on solid lipid nanoparticles and micelles as drug carriers for targeting.
Revolutionising Drug Discovery and Development with Artificial Intelligence
13+ years of healthcare and life sciences industry experience in growth consulting and market intelligence. Aarti Chitale has a strong understanding of pharma and biopharma industry especially the Technology enabled Drug Discovery and Development and Contract Pharma services Industry with keen interest in Emerging Business Models and new growth avenues.
5 Proven Ways to Take PBM’s to the Future ‘Today’ with Conversational AI
Ravi Iyer is a visionary and innovative executive with diverse experience in leading and managing product delivery, client implementation, customer service, and operations with direct responsibility for multimillion-dollar budgets. He has extensive experience delivering across multiple disciplines, including Data Management, Data Governance, Cloud Architecture, Advanced Analytics, Master Data Management, Digital Products, and Digital Transformation. Excellent communicator who works collaboratively to deliver technology strategies and value added solutions that meet the needs of all business functions. Ravi is currently the technology executive and Senior Director at Elevance Health Inc.
Narasimha is result driven leader with vast experience in executing various PBM, Health care, Financial, and securities trading applications. Technical expertise in Big data, Cloud, Analytics, Mainframe, BPM, testing, and Data warehouse projects at esteemed organisations like Anthem, Tetrasoft, DST, HCL, Deutsche bank, and Atos Origin. He currently works as Solution Architect at Tetrasoft Inc. Narasimha has vast experience in Pre-sales, Project management, effective customer communication, Architect, Technical Lead, On-site coordinator, and business Analyst roles for various complex assignments across the globe.
The Unknown Sources of Error in the Pharmaceutical Weighing Process
Thomas Caratsch has been the Head of Laboratory Division since December 2007 at the company's headquarters in Greifensee, Switzerland. Prior to joining the company, Caratsch held various management positions within the Hoffmann La Roche group in the U.S. and Switzerland, including General Manager of Roche Instrument Centre AG and Head of Disetronic Medical Systems AG. He began his career as a development engineer at Sodeco-Saia in Geneva.
Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches
Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.
Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.
press releasesRead more...
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Telix and Ekalia a joint venture between IBA Ion Beam Applications SA EURONEXT and Framatome today announced a collaboration to advance scalable United States US production of astatine At an alphaemitting radioisotope being investigated for targeted alpha therapy
HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases
HistoIndex a pioneer in AIdriven digital pathology for fibrotic diseases and the Agency for Science Technology and Research ASTAR Singapores lead public sector RD agency have signed a Memorandum of Understanding MoU to collaborate on the preclinical evaluation
Cotecna Group Acquires Energon Labs
Cotecna a leading provider of Testing Inspection and Certification TIC services today announced the acquisition of Energon Labs a cGMPcompliant USFDAinspected ISO and ISO certified analytical testing laboratory based in Hyderabad India
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
EventsRead more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWSRead more...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...